diabetes - International Pharmaceutical Industry

Volume 15 Issue 2

How to Harness the Benefits of Inhalation When Re-formulating Biologics

The biologics market is growing rapidly and is on track to be worth $719.14 bn by 2030, up from $366.6 bn in 2021.¹ This growth is being driven primarily by the risi...

3 July 2023 Volume 15 Issue 2 Benefits | biologics

Continue Reading →

Volume 15 Issue 1

How to Take a Safety-first Approach When Harnessing the Power of HPAPIs

In this article, Mike Avraam at ChargePoint Technology explores the challenges of handling HPAPIs safely and discusses how to comply with safety regulations. He expl...

4 April 2023 Volume 15 Issue 1 diabetes | drug

Continue Reading →

News

Positive results from trial of Arecor’s insulin candidate AT247

Therapy demonstrates significantly accelerated insulin absorption and early exposure. Arecor has announced headline results from the second phase 1 clinical trial...

11 October 2022 News artificial pancreas | blood glucose

Continue Reading →

News

Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals

A widely used and inexpensive Type 2 diabetes drug, once hoped to hold enormous promise in treating breast cancer, does not prevent or stop the spread of the most co...

8 December 2021 News breast cancer | Canadian Cancer Trials Group

Continue Reading →

News

EMA to review sotagliflozin as potential treatment for type 1 diabetes

The European Medicines Agency (EMA) has accepted for review Sanofi's regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an add...

29 March 2018 News Agency | diabetes

Continue Reading →

Uncategorised

Real world data back Sanofi’s Toujeo for type I diabetes

Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients with type I diabetes....

20 March 2018 Uncategorised data | diabetes

Continue Reading →

News

Dance Biopharm and Phillips-Medisize Enter into Joint Development Agreement for Advanced Inhaled Insulin Delivery

Dance Biopharm Holdings Inc. (“Dance”), a privately-held biotechnology company focused on the development of Dance 501, a proprietary ‘soft-mist’ inhaled insulin pro...

4 December 2017 News delivery | device

Continue Reading →